Positive attribute framing increases COVID-19 booster vaccine intention for unfamiliar vaccines.

Barnes, K. PhD[1], Colagiuri, B. PhD[1]

[1] *University of Sydney, Australia*

Corresponding Author:
Dr. Kirsten Barnes,
School of Psychology, A18
University of Sydney
NSW 2006
Australia
Email: kirsten.barnes@sydney.edu.au

Abstract

Positive framing has been proposed as a potential intervention to increase COVID-19 vaccination intentions. However, most available research has examined fictitious or unfamiliar treatments. This pre-registered study compared positively and negatively attribute-framed side effect information for real COVID-19 booster vaccines (AstraZeneca, Pfizer, Moderna) and measured intentions pre- and post-intervention in 1,222 UK-based participants. Positive framing increased booster intentions among those with low baseline intentions overall. As hypothesized, however, vaccine familiarity significantly modulated this effect, with positive framing being effective for the least familiar vaccine (i.e., Moderna), while standard negative framing appeared to increase intentions for familiar vaccines (AstraZeneca/Pfizer). These findings provide important new evidence that positive framing could improve vaccine uptake globally when switches or new developments require individuals to receive less familiar vaccines – as is currently the case for millions of booster vaccines across the world. Positive framing of familiar vaccines, however, should be treated with caution.

Introduction

With vaccine efficacy for Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19) waning over time[1,2] and reduced for emerging variants[3,4], many countries are currently accelerating their COVID-19 booster programmes[5,6] to protect against COVID-19 viruses[7,8]. However, vaccine availability does not necessarily translate to vaccine acceptance[9], with the World Health Organization (WHO) recognising vaccine hesitancy as a global health threat[10]. Side effect apprehension is a primary factor driving this hesitancy[11], with one study finding 90% of COVID-19 vaccine refusers feared side effects more than the virus itself[12]. Given the recency of booster programmes, evidence for hesitancy among those already vaccinated is sparse. However, side effect severity associated with previous vaccine doses has already been associated with booster hesitancy in one study[13]. Reducing perceptions of negative side effects could be vital for increasing booster acceptance and thereby reducing the global burden of the current COVID-19 pandemic.

One method of reducing negative perceptions regarding side effects, suggested by the WHO[14], concerns "message framing" of vaccine-relevant information[15]. Positive attribute framing, where side effect information is framed in terms of the inverse incidence rate (e.g., "60% will ***not*** get a sore arm") as opposed to typical negative framing with the standard incidence rate (e.g., "40% will get a sore arm") could be particularly useful for combatting COVID-19 vaccine hesitancy. First, it is directly applicable to side effects. Second, informed consent is maintained as a consequence of statistical consistency across frames[16]. Third, there is preliminary evidence that positive attribute framing can improve vaccination attitudes in other settings. For example, one study on the influenza vaccine found positive attribute framing (hereafter positive framing) reduced the expectation and experience of side effects,

increased perceived protection from influenza, and reduced distortions in the perception of side effect risk[17], with this pattern of results replicated for other vaccine types[18].

Studies examining whether COVID-19 vaccine intention is amenable to framing techniques have produced mixed results[19-21]. However, these studies focused on vaccine-naïve individuals, did not employ attribute framing, and did not concern booster intentions. Critically, existing studies either used fictitious COVID-19 vaccines[19,20] or did not name specific COVID-19 vaccines that at the time were being approved for administration[21]. As such, participants either had limited knowledge of, or investment in, the framed vaccines. As the pandemic has progressed, media discourse[22,23] combined with direct and socially-observed experience of COVID-19 side effects[24], means it is essential to understand whether positive framing is effective for real-world vaccines where prior knowledge and experience exists.

This is particularly important because there is reason to believe that prior knowledge regarding a given COVID-19 vaccine may moderate the strength of any positive framing effect. For example, the increased relevance of, or belief in, a particular treatment or societal issue has been shown to decrease the efficacy of different forms of framing[25,26], including the effect of positive framing on the perception of hypothetical vaccines[25,27]. The effect of positive framing on vaccine intention may therefore be limited to less familiar vaccine types. However, there are two important reasons why attribute framing may still hold utility for COVID-19 vaccines even if limited to unfamiliar vaccines. First, new composition changes to COVID-19 booster vaccines have been recommended[28] and are currently being developed[29] to protect against emerging variants. Second, many booster programmes (e.g., in the United Kingdom) require individuals to switch from their previous COVID-19 vaccine (e.g.,

86 AstraZeneca Vaxzevria). Some alternatives (e.g., Pfizer Cominarty) are more familiar than
87 others (e.g., Moderna Spikevax). As treatment switches have been demonstrated to result in
88 poorer health outcomes and treatment discontinuation in general[30,31], positive framing may be
89 beneficial for increasing uptake for booster switches of this type. However, as medical
90 research on positive framing has tended to focus on fictitious medications and patient
91 scenarios[25,27,32-36], a paucity of evidence exists concerning the effect of familiarity on
92 ecologically valid treatments, especially given the salience of COVID-19 vaccinations at the
93 population level.
94
95 In this pre-registered study (aspredicted.org/53ph4.pdf), conducted in the UK,
96 attribute framing was applied to side effects from genuine manufacturer Patient Information
97 Leaflets (PILs) for the AstraZeneca, Pfizer, and Moderna vaccines. A factorial design was
98 employed, with participants randomised to read positive or negatively framed PILs for the
99 same vaccine they had previously received (either AstraZeneca/Pfizer), a familiar vaccine in
100 the UK context (Pfizer/AstraZeneca), or an unfamiliar vaccine (Moderna). It was
101 hypothesised that a) positive framing would increase booster intention, and b) the effect of
102 positive framing would decrease with vaccine familiarity. Following previous research[16,32,37-
103 39] secondary outcome variables concerning booster side effect severity, perceived risk, and
104 booster acceptance (satisfaction, happiness, anxiety) were explored as potential mediators of
105 the framing effect on vaccine intention.
106
107 **Results**
108 **Overview**
109 Participants (*N*=1,222) were recruited via Pureprofile, an international recruitment
110 service, between 27th October and 8th November 2021. All were pre-screened (see Methods)

with data removed based on pre-registered quality control criteria (see Supplementary Materials 1). Only those who had received two doses of either the AstraZeneca or Pfizer COVID-19 vaccines were eligible to participate, with participants stratified by their previous vaccine type.

Participants from each stratum were subsequently randomised to one of six experimental conditions (3(Familiarity) * 2(Framing) factorial design; see Figure 1). Baseline ratings were collected regarding primary and secondary outcome measures—all recorded on a 100-point VAS. The primary outcome was the participant's intention to receive a booster vaccine. Secondary outcomes were: 1) perceived booster side effect severity; 2) perceived booster risk; 3) booster acceptance (with satisfaction, happiness, and anxiety measured separately). Wording of items can be found in Figure 1. Familiarity with the side effects of the AstraZeneca, Pfizer, and Moderna vaccines were additionally assessed (100-point VAS) to determine whether side effect knowledge corresponded with the predetermined factorial categories of vaccine Familiarity (i.e., Same > Familiar > Unfamiliar).



Figure 1: Sample size, experimental design, and item wording for primary and secondary outcomes

Framed side effect information was subsequently presented dependent on condition. This information took the form of genuine manufacturer PILs for the AstraZeneca, Pfizer, and Moderna vaccines. Side effects were retained in their original form and order and presented in standard EU verbal prevalence categories and frequency bands. Positive framing was applied only to the frequency bands (for example see Figure 2, with full wording and PILs presented as Supplementary Materials 2-3). To manipulate familiarity, participants were randomised to view PILs from the following conditions: 'Same' (PIL for the COVID-19 vaccine previously received: AstraZeneca-AstraZeneca|Pfizer-Pfizer); 'Familiar' (PIL for a common vaccine not previously received: Pfizer-AstraZeneca|AstraZeneca-Pfizer); 'Unfamiliar' (PIL for a less common vaccine in the UK: AstraZeneca-Moderna|Pfizer-Moderna). Familiarity was judged based on UK data (22nd September 2021) outlining that 19.4 and 24.0 million second doses of the Pifzer and AstraZeneca vaccines had been delivered respectively, relative to 1.2 million of Moderna[40]. After timed PIL presentation of 2 minutes, all participants provided post-manipulation ratings for the primary and secondary outcomes (as above). Participants were then presented with 14 side effects from the PIL they had read and were required to: 1) assign each to a verbal prevalence category (i.e., very common, common, uncommon, rare, very rare); 2) estimate frequency of occurrence (number of people in 100,000 expected to experience the side effect.

Negative Attribute Frame (Standard EU Wording)	Positive Attribute Frame	Positive Attribute Frame (Accompanying Infographic)
Common (may affect up to 1 in 10 people)	**Common** (90 in 100 or more people may ***not be affected***)	 **Common:** 90 in 100 (blue circles) or more **not affected**
Uncommon (may affect up to 1 in 100 people)	**Uncommon** (990 in 1,000 or more people may ***not be affected***)	 **Uncommon:** 990 in 1,000 (blue circles) or more **not affected**

Figure 2: Positive and negative wording used to frame common and uncommon side effects (wording for all prevalence categories can be found in Supplementary Materials 2)

Descriptive Statistics

Sample Demographics

Information regarding participant location, age, education, and employment can be found in Figure 2a-b. Participants were 52.5 years of age on average (range=18-95). As presented in Figure 2a, they resided across most postal areas in the UK, with the largest proportion from London district (*N*= 53), Birmingham (*N*=35), and Belfast (*N*=34). Only Harrogate, and the Orkney and Shetland Islands were not represented. Most respondents identified as British (*N*=1,064; 87%). Those self-reporting as female were represented slightly more frequently than other genders (*N*=706; 58%), 34% of the sample had completed undergraduate-level education

161 (*N*=413), and 33% were in full-time employment (*N*=407). Full descriptive statistics for the full
162 sample, and by condition, are presented as Supplementary Materials (4-5).
163
164 ***COVID-19 Exposure and Vaccine History***
165 Most participants (*N*=1,074; 88%) had not personally been infected with COVID-19,
166 while 565 (46%) reported infections among family and close friends. On average, participants
167 had their last COVID-19 vaccine 4.8 months ago. The largest proportion reported not
168 experiencing side effects to either dose (*N*=579; 47%). Of those who did, the first dose was most
169 associated with severe side effects (*N*=372; 30%).



Figure 3: Demographic Information, where 3a plots the frequency of participants from each postal area of the UK against the vaccination rates reported by the UK government on the 3rd November (the final week of data collection) and 3b depicts education and employment categories, and age range, across experimental conditions.

Primary Analysis

Knowledge of vaccine side effects mirrors categorical levels of the Familiarity factor

To determine whether side effect familiarity corresponded with the predetermined factorial categories of Familiarity (i.e., Unfamiliar, Familiar, Same), a within-subjects one-way ANOVA (with Greenhouse–Geisser correction) was run on side effect familiarity ratings collected for the three vaccine types prior to the experimental manipulation. A robust main effect of Familiarity was observed ($F(1.86, 2272.18)=659.17$, $p<.001$, $\eta_p^2=.35$). Awareness of side effects increased with Familiarity; being higher for the Same vs. Familiar vaccine ($t(1221)=14.11$, $p<.001$, Cohen's $d_z=.40$), and for the Familiar vs. Unfamiliar vaccine ($t(1221)=23.97$, $p<.001$, Cohen's $d_z=.69$). Mean differences are presented in Figure 4e.

Baseline Intention to be vaccinated

A 2(Framing) * 3(Familiarity) ANOVA was conducted on Baseline Booster Intention scores to assess the presence of between-group differences on this variable. Levels of Baseline Booster Intention were anticipated to be high across all conditions (see pre-registration), which was confirmed in the present sample ($M=78.36$ (/100-point VAS), $SD=31.65$; range:0-100). However, an unanticipated significant effect of Familiarity was observed on Baseline Booster Intention ($F(2, 1216)=49.51$, $p<.0001$, $\eta_p^2=.075$). This effect reached significance for the orthogonal contrast comparing the Same vs. Other (i.e., combined Familiar and Unfamiliar) vaccine types ($F(1, 1216)=96.51$, $p<.0001$, $\eta_p^2=.074$), but not for the Familiar vs. Unfamiliar comparison ($F(1, 1216)=2.42$, $p=.120$, $\eta_p^2=.002$), indicating higher intentions for previously experienced vaccines.

Effect of framing and familiarity on the intention to be vaccinated

The pre-registered primary analysis plan was a 2(Framing: Positive vs. Negative)*3 (Familiarity: Same Vaccine, Familiar Vaccine, Unfamiliar Vaccine) factorial ANCOVA, with Baseline Booster Intention for the vaccine presented in the participant's assigned PIL as the covariate, and Post-Manipulation Booster Intention the outcome. However, the fact that Baseline Intention unexpectedly differed systematically with Familiarity meant that including it as a covariate without including its interactions with the manipulated variables (Framing and Familiarity) would violate the assumptions of ANCOVA[41]. Therefore, to address this, we extended the model to include the interactions between Baseline Booster Intention and the manipulated variables in all analyses, as has previously been recommended when differences in the covariate exist[42]. Pre-specified orthogonal contrasts for Familiarity were: Contrast1 (Same vs. Other [Familiar and Unfamiliar combined]); Contrast2 (Familiar vs. Unfamiliar). A Framing*Familiarity interaction was hypothesised, with the effect of Framing (increased Booster Intention following Positive vs. Negative framing) reducing with increased Familiarity.

Main effects analysis revealed the anticipated Framing*Familiarity interaction ($F(2, 1210)=10.75$, $p<.0001$, $\eta_p^2=.018$). Specifically, Framing interacted with Contrast1 (Same vs. Other: $F(1, 1210)=5.07$, $p=.025$, $\eta_p^2=.004$) and Contrast2 (Familiar vs. Unfamiliar: $F(1, 1210)=16.46$, $p=.0001$, $\eta_p^2=.013$). As demonstrated in Figure 4a which depicts the interaction means, this pattern of results was driven by Positive Framing increasing Booster Intention for the Unfamiliar vaccine. However, this was superseded by a three-way interaction with Baseline Booster Intention ($F(2, 1210)=7.65$, $p=.0005$, $\eta_p^2=.013$), represented at both Contrasts (Baseline*Framing*Contrast1: $F(1, 1210)=4.39$, $p=.036$, $\eta_p^2=.004$ |

220 Baseline*Framing*Contrast2: $F(1, 1210)=11.19$, $p=.0008$, $\eta_p^2=.009$). Data presented in Figure
221 4b, that depicts this interaction, provides a more nuanced understanding of results. Viewing side
222 effect information of any type appeared to increase average Booster Intention (i.e., post-
223 manipulation model estimated means were above zero, for all levels of the baseline covariate).
224 Positive Framing had limited efficacy at high levels of Baseline Intention across Conditions but
225 took effect for the Unfamiliar Vaccine when model estimated VAS scores were lower than
226 ~80/100. At very low levels of Baseline Intention (i.e., VAS=0), model predicted Booster
227 Intention Post-Manipulation increased from *M*=19.09 (*SEM*=2.76, 95% CIs[13.68, 24.50]) for
228 the Negative Frame, to *M*=35.11 (*SEM*=2.77, 95% CIs[29.68, 40.50]) for the Positive Frame.
229 Full model output is included as Supplementary Materials 6. We note that the same interaction
230 between Framing and Familiarity was observed in the planned but invalid model excluding the
231 interaction between these factors and Baseline Booster Intention (see Supplementary Materials
232 7).
233
234 ***The effect of positive framing on vaccine switches***
235 Analyses were performed to investigate the effect of framing on pre-registered and
236 realistic vaccine switches occurring as part of the UK's booster programme. Specifically, those
237 without medical exemption, who previously received the AstraZeneca vaccine will be required to
238 switch to Pfizer or Moderna, while those who received Pfizer may be required to switch to
239 Moderna.
240 First, previous vaccine type (AstraZeneca/Pfizer) was entered as a factor in the
241 ANCOVA model above to check for interactions with Framing, Familiarity, and Baseline
242 Booster Intention. While there was a main effect of previous vaccine type ($F(1, 1198)=6.36$,

243 p=.012, η_p^2=.005), with those receiving AstraZeneca reporting increased Booster Intention
244 (M=80.83, SEM= 0.74, 95% CIs [79.37, 82.29]) compared to Pfizer (M=78.01, SEM= 0.74, 95%
245 CIs [76.57, 79.46]), there were no two- or three-way interactions with Framing or Familiarity (all
246 ps>.05; see Supplementary Materials 8).
247
248 ***Previous Vaccine: AstraZeneca***
249 Representative of a switch from AstraZeneca to Pfizer or Moderna, a
250 2(Framing)*2(Familiarity: Familiar (Pfizer), Unfamiliar (Moderna)) ANCOVA, with
251 interactions between the covariate (Baseline Booster Intention) and factors modelled, was
252 conducted among those who had previously received the AstraZeneca vaccine (N=410). A three-
253 way Framing*Familiarity*Baseline Intention interaction was observed (F(1, 402)=11.38,
254 p=.0008, η_p^2=.028). As demonstrated in Figure 4c, in the case of the Unfamiliar vaccine
255 (Moderna) Booster Intention was increased in the Positive Frame at low levels of Baseline
256 Booster Intention. However, the inverse of this pattern was observed for the Familiar vaccine
257 (Pfizer), where Positive Framing decreased Booster Intention at low levels of Baseline Intention.
258
259 ***Previous Vaccine: Pfizer***
260 Representative of a switch from Pfizer to Moderna, a one-way ANCOVA investigating
261 the effect of framing on the perception of the Unfamiliar (i.e., Moderna) PIL was performed on
262 the data of those who had previously received the Pfizer vaccine (N=202). There was a main
263 effect of Framing (F(1, 198)=3.98, p=.048, η_p^2=.020), but no statistically significant Baseline
264 Booster Intention*Framing interaction (F(1, 198)=1.80, p=.181, η_p^2=.009). However, as

265 demonstrated in Figure 4d, slopes for the Positive and Negative Frame converged at high levels

266 of Baseline Booster Intention.

267



268

269 Figure 4: Model estimated mean differences in the primary outcome (Booster Intention),

270 depicted for the whole sample (4a and 4b), and for realistic switches occurring as part of the UK

271 booster programme (4c and 4d). 4e presents data demonstrating that side effect familiarity

272 ratings scaled with the factorial levels of Vaccine Familiarity. All error bars represent ± 1SEM.

273

274 **Secondary Analyses**

275 ***Positive framing decreases the perception of booster side effect severity***

Perceived side effect severity associated with the vaccines was measured pre- and post-manipulation. A 2(Framing)*3(Familiarity) ANCOVA (contrasts as above), including interactions with the covariate (Baseline Side Effect Severity), revealed a main effect of Framing ($F(1, 1210)=3.92$, $p=.048$, $\eta_p^2=.003$), and a Baseline Severity*Framing interaction ($F(1, 1210)=4.52$, $p=.034$, $\eta_p^2=.004$). There were no other two- or three-way interactions (all *ps*>.35). As depicted in Figure 5a, reading about side effects in any frame increased the perception of their severity (i.e., post-manipulation model estimated means are above zero, for all levels of the baseline covariate). However, Positive Framing resulted in a lower perception of side effect severity, which was strongest when side effects were perceived as severe at baseline. Full model output is included as Supplementary Materials 8.

Perception of booster vaccine risk decreases with vaccine familiarity

Perception of risk to participant's health associated with receiving the vaccines was recorded pre- and post-manipulation. The main effect of Framing did not reach statistical significance ($F(1, 1210)=1.04$, $p=.308$, $\eta_p^2=.001$). There was a Familiarity*Baseline Risk Perception interaction ($F(2, 1210)=4.82$, $p=.008$, $\eta_p^2=.008$), evident in both contrasts (Baseline Risk*Contrast1: $F(1, 1210)=4.28$, $p=.039$, $\eta_p^2=.004$ | Baseline Risk*Contrast2: $F(1, 1210)=6.03$, $p=.014$, $\eta_p^2=.005$). No other statistically significant main effects or interactions were observed (all *ps*>.10). As depicted in Figure 5b, there was limited difference between Familiarity conditions when the perception of risk was low at baseline. At high levels of Baseline Risk, Post-Manipulation Risk Perception was lowest for the previously experienced vaccine and highest for the Unfamiliar vaccine. Full model output is included as Supplementary Materials 10.

Positive framing increases satisfaction and happiness with the framed booster but does not reduce anxiety

At pre- and post-manipulation, participants were asked to imagine that the framed vaccine was their only option for a booster and to rate their Satisfaction, Happiness and Anxiety regarding this outcome. In order to reduce the data for analysis, the three variables were entered into a principal components analysis. Component loading suggested that Satisfaction and Happiness loaded onto a similar latent construct, while Anxiety was associated with another. Therefore, Satisfaction and Happiness were averaged together for the subsequent analyses, while Anxiety was treated separately. Two ANCOVAs were run on these outcomes. The first revealed a main effect of Framing ($F(1, 1210)=5.66$, $p=.018$, $\eta_p^2=.005$) and a Framing*Familiarity ($F(2, 1210)=3.63$, $p=.027$, $\eta_p^2=.006$) and Baseline Satisfaction/Happiness*Framing*Familiarity ($F(2, 1210)=3.43$, $p=.033$, $\eta_p^2=.006$) interaction. This three-way interaction was significant for Contrast1 (Same vs. Other: $F(1, 1210)=4.11$, $p=.043$, $\eta_p^2=.003$), but not Contrast2 (Familiar vs. Unfamiliar: $F(1, 1210)=2.56$, $p=.110$, $\eta_p^2=.002$). As shown in Figure 5c, for the Same and Unfamiliar vaccines, lowered satisfaction and happiness were generally associated with Negative Framing, particularly at low levels of Baseline Satisfaction/Happiness. There appeared to be no difference for the Familiar vaccine.

With respect to anxiety, there was a significant Baseline Anxiety*Framing interaction ($F(1, 1210)=5.53$, $p=.019$, $\eta_p^2=.005$), but no other main effects or interactions (all $ps>.05$). As shown in Figure 5d, Positive Framing appeared to increase Post-Manipulation Anxiety at very high levels of Baseline Anxiety, but was limited to the Same Condition (i.e., among participants who had high Baseline Anxiety regarding continuation with their previous vaccine type), with

this interaction nearing significance (Anxiety*Framing*Contrast1: $F(1, 1210)=3.65$, $p=.056$, $\eta_p^2=.003$). Correlations, PCA, and Models are presented as Supplementary Materials 11.



Figure 5: Mean values for secondary outcome measures, where 5a depicts model-estimated mean differences regarding side effect severity ratings, 5b perceptions of vaccine risk, 5c combined satisfaction and happiness associated with the framed vaccine, and 5d anxiety surrounding the framed vaccine. All error bars represent ± 1SEM.

Positive framing influences judgements regarding side effect prevalence

Participants were required to classify 14 side effects from their assigned PIL into verbal prevalence categories, as well as provide a frequency estimate regarding how many people, in 100,000, they thought would experience each side effect if they received the framed vaccine. Eleven side effects were associated with discrete prevalence categories. Three were presented in the PILs as of 'unknown prevalence'. Raw frequency estimates of the latter were analysed separately to test whether framing alters perceptions regarding prevalence when no information is provided. Side effects from each PIL are included as Supplementary Materials 12. For side effects with a concrete category, the percentage of side effects correctly assigned across verbal prevalence categories, and frequency bands, were computed as outcome measures. Frequency estimates were judged correct based on the following frequency bands[39]: Very Common = 10,001–100,000 (>10%); Common = 1001–10,000 (>1–10%); Uncommon = 101–1000 (>0.1–1%); Rare = 11–100 (>0.01–0.1%); Very Rare = 0–10 (0–0.01%). ANOVAs were performed with Framing and Familiarity as factors.

Verbal Prevalence Categories

As depicted in Figure 6a, a main effect of Framing ($F(1, 1216)=5.54$, $p=.019$, $\eta_p^2=.005$) was observed, while Familiarity neared significance ($F(2, 1216)=2.98$, $p=.051$, $\eta_p^2=.005$). This was driven by Contrast1 only (Same vs. Other: $F(1, 1216)=4.93$, $p=.027$, $\eta_p^2=.004$). While accuracy was generally low, fewer accurate classifications were made following Positive Framing (M=30.9%, SEM=0.73, 95% CIs [29.46, 32.31]), relative to Negative Framing (M=33.3%, SEM=0.73, 95% CIs [31.87, 43.73]). While the reduction in accuracy associated with positive, relative to negative, framing appeared to decrease with familiarity, the

Framing*Contrast1(Same vs. Other) interaction did not reach statistical significance ($F(1, 1216)=3.11$, $p=.078$, $\eta_p^2=.003$). Full model output is included as Supplementary Materials 13.

Frequency Estimates

A main effect of Framing ($F(1, 1216)=6.45$, $p=.011$, $\eta_p^2=.005$) and Familiarity ($F(2, 1216)=9.71$, $p=.0001$, $\eta_p^2=.016$) was observed. As depicted in Figure 6b, accuracy was reduced with Positive Framing, but increased with Familiarity. Contrast1 (Same vs. Other: $F(1, 1216)=9.52$, $p=.002$, $\eta_p^2=.008$) and Contrast2 (Familiar vs. Unfamiliar: $F(1, 1216)=9.84$, $p=.002$, $\eta_p^2=.008$) reached significance. Overall, participants frequency estimates were less accurate following positive framing (*M*=20.7%, *SEM*=0.74, 95% CIs [19.40, 22.32]) relative to negative framing (*M*=23.54%, *SEM*=0.74, 95% CIs [22.08, 25.00]). Framing did not interact with the main effect of Familiarity, or the orthogonal contrasts (all *ps*>.30). Full model output is included as Supplementary Materials 14.

Neither Framing nor Familiarity had any effect on frequency estimates of side effects of 'unknown' frequency (all *ps*>.16; see Supplementary Materials 15). Those in the Positive Framing conditions estimated that these side effects would be experienced by 1,848/100,000 people on average, and those in the Negative Frame as 2,004/100,000.



Figure 6: Mean percentage of correct category (6a) and frequency (6b) judgements. All error bars represent ± 1SEM.

Discussion

Message framing has been suggested as a potential intervention to increase COVID-19 vaccine uptake[14]. In the present study, positive and negative attribute framing was applied to genuine side effect information from manufacturer PILs for three COVID-19 vaccines (AstraZeneca, Pfizer, Moderna). Booster intention was measured pre- and post-manipulation. Primary analysis revealed that positive framing successfully increased the intention to be vaccinated for unfamiliar vaccines (i.e., Moderna), but appeared to reduce booster intention for the vaccine that had previously been received, as well as for a switch to the Pfizer vaccine among those previously receiving AstraZeneca. In all cases, effects were strongest when baseline booster intentions were low. Increasing booster acceptance among those with low intentions is of substantial importance in protecting against infection from, and transmission of, COVID-19 viruses. Our data suggest that any intervention that intends to employ attribute framing should be

388 carefully tailored to match the framed information (i.e., positive vs. negative wording) with
389 vaccine familiarity. Specifically, positive framing appears to have significant potential when the
390 vaccine is unfamiliar, such as in situations such when a novel vaccine is being introduced or
391 there are composition changes to the vaccine[28,29]. By contrast, our data also suggest that positive
392 framing may actually be harmful when the vaccine is familiar.
393
394 The significant effect of positive attribute framing on booster intentions for the
395 Unfamiliar vaccine is consistent with research concerning medical decision making. In those
396 studies, framed information has typically been presented regarding fictitious medications and
397 patient scenarios[25,27,32-36]. In other cases using real treatments, data has been collected from
398 samples where participants were either completely[17,43] or largely[44] naïve to the framed treatment,
399 or where prior treatment experience was not assessed[18,45]. The current data thereby provide new
400 insights into the effect of framing. Under conditions directly relevant to the COVID-19 pandemic
401 (i.e., for real vaccines, at high levels of public involvement), the benefit of positive attribute
402 framing was found to wane, or in some instances to be reversed, as familiarity and prior
403 experience with the framed vaccine increased. As such, calls for all PILs to employ positive
404 framing as standard (e.g.,[32,46]) appear premature. Positive framing appears beneficial only for
405 unfamiliar vaccines whereas negative framing, the standard form for communicating side effect
406 information within the European Union, appears beneficial when treatments are well known.
407
408 The reduced efficacy of positive framing observed as vaccine familiarity increased could
409 be explained by a current theory of attribute framing that posits an interaction between
410 familiarity (a specific manifestation of psychological distance) and the valence of the message

411 surrounding a given attribute or event (e.g., the experience of vaccine side effects). At closer
412 psychological distances (e.g., for vaccines that are more familiar and more likely to be received),
413 negatively framed information has been shown to be more persuasive[47]. Further experimental
414 research is needed to test this theory, while also considering alternative explanations, such as the
415 role of potential backfire effects in persuasive or corrective messaging that are known to impact
416 attitudes surrounding the COVID-19 pandemic[48] and have been demonstrated to lower intentions
417 for other vaccine types at high levels of concern[49]. However, when assessed in conjunction,
418 results presented here highlight the fact that any intervention that strives to apply positive
419 framing across all vaccine types irrespective of familiarity should be treated with caution.
420
421 Perceived booster side effect severity, perceived booster risk, and booster acceptance
422 (satisfaction, happiness, and anxiety) were examined as secondary variables to explore potential
423 mediators of the effect of positive framing on booster intention. None of the patterns of these
424 secondary variables mirrored the results obtained for the primary outcome – booster intention.
425 Instead, positive framing appeared to have a more general capacity to increase favourable
426 perceptions of the COVID-19 vaccines, decreasing perceptions of side effect severity, and
427 increasing satisfaction and happiness in some instances. These results may appear difficult to
428 reconcile with the observed changes in vaccine intention. However, post-hoc analysis (see
429 Supplementary Materials 15) plotting the Familiarity*Framing*Baseline interaction on side
430 effect severity and booster acceptance for those who had high vs. low baseline booster intent,
431 suggests that framing-induced changes on these secondary variables largely occurred among
432 those with high vaccine intention at baseline. Notably, participants with high baseline booster
433 intentions showed limited effect of framing on their behavioural intention to be vaccinated. Thus,

434 rather than being inconsistent with the primary outcome data, this exploratory pattern of results
435 simply suggests that changes in booster intention with framing are unlikely to driven by changes
436 in the perception of the COVID-19 vaccines as measured here. Investigation of other factors
437 combined with qualitative research may be better positioned to identify the driving factors
438 behind changes in booster intention that occur with the framing of COVID-19 vaccinations.
439
440 Estimates of side effect prevalence were found to be quite poor (<~35% accuracy) after
441 reading the information contained in the PILs, irrespective of frame. This is consistent with
442 previous research[39,50-53] and highlights limitations with the current format of communicating side
443 effect information. It was interesting to note that an additional reduction in accuracy was also
444 observed for the positive frame, which did not interact with familiarity. However, patterns within
445 the data were inconsistent, with reduced accuracy associated with the Unfamiliar vaccine
446 appearing exacerbated for verbal prevalence categories but ameliorated for frequency estimates.
447 As such, it is unclear whether positive framing has the potential to undermine informed consent[16]
448 by reducing accuracy concerning side effect prevalence. Further, because the present study
449 employed genuine PILs, the side effects participants were required to judge differed across
450 vaccine types. As such, the study was designed only to test for general inaccuracies in side effect
451 representation and not systematic over- or under-estimation. Experimental studies are therefore
452 needed to assess precisely how any inaccuracies associated with positively framed COVID-19
453 vaccine information manifest.
454
455 The primary strength of the present study is the application of attribute framing to real
456 COVID-19 vaccines with real PILs. The PILs employed here are displayed on government and

457 NHS websites in the UK, forming a primary official source of information regarding COVID-19
458 vaccination. Our findings therefore have real-world implications, demonstrating that the wording
459 of PILs can directly impact the intention to receive a booster vaccine among individuals for
460 whom this decision is both directly relevant and imminent. There are of course some limitations
461 worth noting including the collection of cross-sectional data that limits an assessment of the
462 durability of the framing effect, as well as a sample located within a single country. Given global
463 differences in booster policy, cross-cultural replication of results is required to ensure that the
464 data presented here is not contextually limited to the UK. While vaccine intention has been
465 demonstrated to be a strong predictor of vaccine uptake[e.g.,[54-56]], including for COVID-19
466 vaccination[57], we do not assume that the two are synonymous[58]. While beyond the scope of the
467 present study, we recommend that future research incorporate longitudinal designs where the rate
468 of conversion from intention to vaccine uptake can be tracked. Further, the results presented here
469 are specific to booster intentions among those already vaccinated. While side effect apprehension
470 has been associated with hesitancy regarding COVID-19 vaccination[11] and booster vaccination[13],
471 whether a similar pattern of results would hold among those who have never been vaccinated is
472 unknown.
473
474 In summary, the present study demonstrates that the ability of positive framing to
475 successfully increase booster intention for genuine COVID-19 vaccines is critically moderated
476 by the familiarity of that vaccine. Positive framing can improve vaccine intention for unfamiliar
477 vaccines, but may actually decrease intentions for familiar vaccines. The data therefore provide
478 novel insights into the benefits of positive framing for COVID-19 vaccines and beyond. As such,
479 we recommend that if positive attribute framing is to be employed, close attention must be paid

to the type of treatment being framed as well as the likely recipients of the framed information. Importantly, in the context of the current COVID-19 pandemic, positive framing appears capable of improving uptake of COVID-19 vaccines when switches or new developments require individuals to receive unfamiliar vaccines, as is the case for many booster vaccine programmes globally, but should be treated with caution for familiar vaccines.

Methods

Recruitment and Sample

Recruitment took place in the initial weeks of the UK booster programme (27th October - 8th November 2021). Figure 3a provides a summary of the number of boosters administered in the UK at the time of data collection. The sample was obtained from Pureprofile, an ISO-certified panel provider for online research, and balanced on national quotas for age, gender, and region. All potential participants were screened using the following inclusion criteria: 18 years of age or older, currently residing in the UK, self-reported English fluency, previously received two doses of either the Pfizer or the AstraZeneca COVID-19 vaccines (no other combination), not having received a third COVID-19 booster vaccine, and no known medical reason (e.g., allergy) prohibiting potential administration of the Pfizer, AstraZeneca, or Moderna COVID-19 vaccines. After screening, 1896 participants provided electronic consent and 1459 completed the experiment. To reduce statistical noise due to random and inconsistent responding, 237 completing participants were removed based on pre-registered quality control criteria (see Supplementary Materials). The experiment was approved by the University of Sydney Human Research Ethics Committee. All completing participants were provided with an electronic debrief at the end of the survey and were paid £3.50 for a ~15-minute survey.

503

504 **Data Collection and Procedure**

505 Cross-sectional data were collected online via Qualtrics, with the survey accessible to
506 personal computer, tablet, and smartphone. The 'force response' option was used to ensure
507 complete cases for all outcome variables. Participants completed the survey in one sitting and
508 were not able to return to the study URL. After pre-screening, those meeting the inclusion
509 criteria were provided with a participant information statement detailing the aims of the study
510 and gave their digital informed consent. Those not meeting these criteria were directed away
511 from the survey.

512 Participants completed demographic items and identified which COVID-19 vaccine they
513 had previously received (AstraZeneca or Pfizer). Stratified randomisation to the six experimental
514 groups occurred at this point using the inbuilt Qualtrics randomisation function. Quotas were set
515 to limit data collection to 600 participants from each vaccine type (AstraZeneca/Pfizer), with 100
516 from each group randomised to the six experimental conditions. Because Qualtrics tallies quotas
517 on survey completion but does not account for participants currently in the experimental
518 pipeline, the final sample contained 22 more participants than projected. Statistical analysis did
519 not take place until after exclusions had been made and all quotas were closed.

520

521 After randomisation, participants responded to items concerning the number of months
522 since their last COVID-19 vaccine and familiarity with side effects of the three framed vaccines.
523 For each vaccine type, participants then rated their booster intention, perceived booster side
524 effect severity, perceived booster risk, and booster acceptance (satisfaction, happiness, and
525 anxiety). Responses made to the vaccine type that matched with the experimental condition to

526 which the participant had been assigned were employed as baseline measures. Responses to all
527 other vaccine types were recorded for use in a concurrent, but separate, pre-registered study
528 (#78370; aspredicted.org/8e6af.pdf). PILs containing the positively or negatively framed side
529 effect information were then displayed for two minutes, using a timer embedded in the survey.
530 Participants could not proceed until this time had elapsed. Post-manipulation booster intention,
531 perceived booster side effect severity, perceived booster risk, and booster acceptance were then
532 recorded. Finally, fourteen side effects described in the PILs were presented, with participants
533 required to assign each to a verbal prevalence descriptor (very common, common, uncommon,
534 rare, very rare) and estimate how many people (out of 100,000) taking the vaccine would
535 experience the side effect. On completing the survey, all participants were provided with an
536 electronic debrief for download and URLs to the UK government landing page where the
537 original PILs for the vaccines used in the study could be found.
538
539 Several additional items concerning general COVID-19 booster intentions, perceived risk
540 of previous COVID-19 vaccines, specific COVD-19 vaccination side effects, general perceptions
541 of COVID-19 and COVID-19 vaccinations, and severity of previous COVID-19 infection, were
542 included in the survey for use in a separate pre-registered study (#78370;
543 aspredicted.org/8e6af.pdf), but are not analysed or reported on here.
544

545 **Survey Materials**

546 ***Demographic Information***

547 Participants responded to items concerning their age, gender, ethnicity, highest level of
548 education and employment status, and geographic region (postal area code). Exact wording can
549 be found in the Demographic Information section, Supplementary Materials 4.

550

551 ***Previous exposure to COVID-19***

552 Items were employed to capture personal exposure to COVID-19, as well as exposure
553 through close friends and family. Item wording (*To your knowledge, are you, or have you been,*
554 *infected with COVID-19? / To your knowledge, have any of your close family members or friends*
555 *been infected with COVID-19?)* was taken from the WHO BeSD documentation[14].

556

557 ***Previous COVID-19 Vaccination History***

558 Previous COVID-19 vaccine (Pfizer/AstraZeneca) was recorded as a forced-choice
559 option. Participants indicated the number of months since their last COVID-19 vaccine, and
560 whether their most severe side effects occurred to their first dose, second dose, whether they
561 were equal across doses, or not experienced at all.

562

563 ***Familiarity with COVID-19 vaccine side effects***

564 For the three framed vaccines, participants were asked to rate their "*familiarity with the*
565 *potential side effects*" on a 100-point VAS, with anchor labels (*'not at all familiar'* / *'extremely*
566 *familiar'*) positioned to the left and right of the scale. Those who had not heard of the vaccine
567 were asked to check a separate '*not heard of vaccine'* box but received a score of zero (*not at all*
568 *familiar*). This response-type was used to exclude inconsistent responders (see Supplementary
569 Materials 1).
570
571 ***Baseline Measures: COVID-19 Vaccine Perceptions***
572 Four items were used as baseline measures. All were rated on a 100-point VAS. For each
573 of the three vaccines, participants responded to questions concerning: 1) booster intention '*If you*
574 *were offered* [vaccine type] *as a booster vaccine to maintain protection against COVID-19*
575 *viruses, how likely would you be to accept?*' (labels: 'definitely would not accept vaccine' vs.
576 'definitely would accept vaccine'); 2) perceived booster side effect severity '*Overall, how severe*
577 *do you think the* [vaccine type] *side effects are?*' (labels: 'not at all severe' vs. 'extremely
578 severe'); 3) perceived booster risk '*What do you think the risk to your health would be if you*
579 *received* [vaccine type] *as a booster vaccine, bearing in mind its side effects?*' (labels:
580 'extremely low risk' vs. 'extremely high risk'); 4) booster switch perceptions '*Imagine that*
581 *switching to the* [vaccine type] *vaccine was your only option for a booster. Please rate how*
582 *satisfied, happy, and anxious, you would be with this outcome'* (labels: 'not at all' vs.
583 'extremely'). Satisfaction, happiness, and anxiety were rated as sub-items, each yielding a score
584 of 0 – 100. Where the vaccine type was the same as that previously received by the participant,
585 wording was changed from 'switching to' to 'continuing with'. Wording of 1 – 3 was adapted
586 from previous research[39].

587

588 ***Patient Information Leaflets (PILs): Experimental Manipulation***

589 Genuine PILs for the AstraZeneca, Pfizer, and Moderna vaccine were abridged to include
590 the manufacturer's description of each vaccine, what it is used for, and critically, the possible
591 side effects resulting from administration. Side effects were retained in their original form and
592 order. For both the negatively and positively framed PILs, verbal descriptors were in keeping
593 with those published by the manufacturer (i.e., very common, common, uncommon, rare, very
594 rare, not known). Wording of assigned frequency bands employed in the negatively framed PILs
595 was also identical to that of the manufacturer. However, this was inverted in the positively
596 framed PILs to stress the number of individuals *not* affected (e.g., "Common (90 in 100 or more
597 people may *not be affected*)"). As multi-modal forms of side effect presentation (e.g., written,
598 pictorial, verbal) may elicit larger framing effects[16], and numeracy is less likely to moderate the
599 effect of attribute framing for graphical presentations[59], positive PILs additionally included a
600 graphical representation of side effect risk to enhance the manipulation. For an example of the
601 wording used to frame side effects see Figure 2.

602

603 ***Post-Manipulation Measures: COVID-19 Vaccine Perceptions***

604 Participants responded to the four vaccine perception items listed above under Baseline
605 Measures (booster intention, booster side effect severity, booster risk, booster acceptance), but
606 only in relation to the vaccine type outlined in the PIL to which they were assigned.

607

608 ***Post-Manipulation Side Effect Perceptions***

To determine whether positive framing augments the perception of side effect occurrence relative to true prevalence rates, fourteen side effects were presented from each PIL. Eleven of these were associated with concrete prevalence brackets in the original PILs, while the remaining three were assigned to the 'unknown' category (i.e., could not be estimated at the time of PIL publication). For each side effect, participants were required to identify the correct verbal descriptor (very common, common, uncommon, rare, very rare): "*based on the information that you read, how common do you think [side effect] is?"* (forced-choice answer). They were then asked, "*In 100,000 people, how many do you think would experience* [side effect] *if they received a* [framed vaccine name] *booster vaccine?"* (free-response, limited to numbers at up to 10 decimal places). The three 'unknown' side effects were analysed separately to determine the effect of framing when prevalence rates are not provided.

Statistical Analysis

Statistical analysis was performed using R (version 4.1.1). Statistical analyses were a combination of ANCOVAs (where baseline measures were available) or ANOVAs, reported with Type III Sum of Squares. An alpha of .05 was accepted as the threshold for statistical significance. Sample size (estimated N=1200) was calculated based on an *a priori* power analysis (95% power, alpha=.05, effect size f^2=0.02) for a separate study run concurrently that contained more predictor variables (N=9), and therefore required more power, than the study presented here (further details are contained in the study pre-registration form). An effect size for attribute framing was additionally derived from previous research (average effect size r= 0.175)[16]. An *a priori* power analysis based on this effect size required a total of 491 participants, providing

reassurance that the projected sample size for the study above provided ample power to detect an effect of framing in the present study.

Acknowledgements

Sources of Funding: This research was supported by Australian Research Council grants DP180102061 and DP200101748. The funding body had no involvement in study design, analysis, interpretation, writing, or the decision to submit the present article for publication.

Data Availability: The code and raw data necessary to replicate the reported analysis is available through the Open Science Framework repository (means/SEMs needed to reproduce the analysis figures are included with the raw data):
https://osf.io/d5cvn/?view_only=500c83d90bb9416796e464108ad2fc41

Author contributions: KB and BC conceived the experimental design. KB was responsible for collecting and analysing the data. KB wrote the first draft of the article. BC edited and contributed to the final version.

References

1 Andrews, N. *et al.* Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK. Preprint at: https://www.medrxiv.org/content/10.1101/2021.09.15.21263583v2 (2021).

2 Goldberg, Y. *et al.* Waning immunity of the BNT162b2 vaccine: A nationwide study from Israel. Preprint at: https://www.medrxiv.org/content/10.1101/2021.08.24.21262423v1(2021).

656 3 Cele, S. *et al.* SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer
657 BNT162b2 elicited neutralization and requires ACE2 for infection. Preprint at:
658 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669855.2/ (2021).
659 4 Basile, K. *et al.* Improved neutralization of the SARS-CoV-2 Omicron variant after
660 Pfizer-BioNTech BNT162b2 COVID-19 vaccine boosting. Preprint at:
661 https://www.biorxiv.org/content/10.1101/2021.12.12.472252v1.abstract (2021).
662 5 Mahase, E. Covid-19 booster vaccines: What we know and who's doing what. *BMJ* **374**,
663 n2082 (2021).
664 6 *All adults to be offered COVID-19 boosters by end of January* (gov.uk, 2021);
665 https://www.gov.uk/government/news/all-adults-to-be-offered-covid-19-boosters-by-end-
666 of-january
667 7 Gardner, B. J. & Kilpatrick, A. M. Third doses of COVID-19 vaccines reduce infection
668 and transmission of SARS-CoV-2 and could prevent future surges in some populations: a
669 modeling study. Preprint at:
670 https://www.medrxiv.org/content/10.1101/2021.10.25.21265500v3 (2021).
671 8 Ireland, G. *et al.* Serological responses to COVID-19 booster vaccine in England.
672 Preprint at: https://www.medrxiv.org/content/10.1101/2021.11.22.21266692v1(2021).
673 9 MacDonald, N. E. Vaccine hesitancy: Definition, scope and determinants. *Vaccine* **33**,
674 4161-4164 (2015).
675 10 *Ten threats to global health in 2019* (World Health Organisation, 2019);
676 https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019
677 11 Solís Arce, J. S. *et al.* COVID-19 vaccine acceptance and hesitancy in low- and middle-
678 income countries. *Nature Medicine* **27**, 1385-1394 (2021).
679 12 *Why won't Americans get vaccinated?* (Economist/YouGov poll, 2021);
680 https://today.yougov.com/topics/politics/articles-reports/2021/07/15/why-wont-
681 americans-get-vaccinated-poll-data
682 13 Rzymski, P., Poniedziałek, B. & Fal, A. Willingness to Receive the Booster COVID-19
683 Vaccine Dose in Poland. *Vaccines* **9**, 1286 (2021).
684 14 *World Health Organization. Data for action: achieving high uptake of COVID-19*
685 *vaccines: gathering and using data on the behavioural and social drivers of vaccination:*
686 *a guidebook for immunization programmes and implementing partners: interim*

687 *guidance, 1 April 2021.* (World Health Organization, 2021);
688 https://apps.who.int/iris/handle/10665/340645
689 15 Levin, I. P., Schneider, S. L. & Gaeth, G. J. All Frames Are Not Created Equal: A
690 Typology and Critical Analysis of Framing Effects. *Organizational Behavior and Human*
691 *Decision Processes* **76**, 149-188 (1998).
692 16 Barnes, K. *et al.* Can Positive Framing Reduce Nocebo Side Effects? Current Evidence
693 and Recommendation for Future Research. *Frontiers in Pharmacology* **10**, 167 (2019).
694 17 O'Connor, A. M., Pennie, R. A. & Dales, R. E. Framing effects on expectations,
695 decisions, and side effects experienced: The case of influenza immunization. *Journal of*
696 *Clinical Epidemiology* **49**, 1271-1276 (1996).
697 18 Bigman, C. A., Cappella, J. N. & Hornik, R. C. Effective or ineffective: Attribute framing
698 and the human papillomavirus (HPV) vaccine. *Patient Education and Counseling* **81**,
699 S70-S76 (2010).
700 19 Sudharsanan, N., Favaretti, C., Hachaturyan, V., Bärnighausen, T. & Vandormael, A.
701 Effects of Side-Effect Risk Framing Strategies on COVID-19 Vaccine Intentions in the
702 United States and the United Kingdom: A Randomized Controlled Trial. Preprint at:
703 https://www.medrxiv.org/content/10.1101/2021.10.12.21264877v2 (2021).
704 20 Chen, T., Dai, M., Xia, S. & Zhou, Y. Do Messages Matter? Investigating the Combined
705 Effects of Framing, Outcome Uncertainty, and Number Format on COVID-19
706 Vaccination Attitudes and Intention. *Health Communication*, 1-8 (2021).
707 21 Huang, Y. & Liu, W. Promoting COVID-19 Vaccination: The Interplay of Message
708 Framing, Psychological Uncertainty, and Public Agency as a Message Source. *Science*
709 *Communication* **44**, 3-29 (2021).
710 22 Lentzen, M.-P. *et al.* A retrospective analysis of social media posts pertaining to COVID-
711 19 vaccination side effects. *Vaccine* **40**, 43-51 (2022).
712 23 Jamison, A. M. *et al.* Vaccine-related advertising in the Facebook Ad Archive. *Vaccine*
713 **38**, 512-520 (2020).
714 24 Ndwandwe, D. & Wiysonge, C. S. COVID-19 vaccines. *Current Opinion in Immunology*
715 **71**, 111-116 (2021).

716 25 Donovan, R. J. & Jalleh, G. Positive versus Negative Framing of a Hypothetical Infant
717 Immunization: The Influence of Involvement. *Health Education & Behavior* **27**, 82-95
718 (2000).
719 26 Benjamin, D., Por, H.-H. & Budescu, D. Climate Change Versus Global Warming: Who
720 Is Susceptible to the Framing of Climate Change? *Environment and Behavior* **49**, 745-
721 770 (2016).
722 27 Haydarov, R. & Gordon, J. C. Effect of combining attribute and goal framing within
723 messages to change vaccination behavior. *Journal of Communication in Healthcare* **8**,
724 45-54 (2015).
725 28 *Interim Statement on COVID-19 vaccines in the context of the circulation of the Omicron*
726 *SARS-CoV-2 Variant from the WHO Technical Advisory Group on COVID-19 Vaccine*
727 *Composition (TAG-CO-VAC)* (World Health Organization, 2022);
728 https://www.who.int/news/item/11-01-2022-interim-statement-on-covid-19-vaccines-in-
729 the-context-of-the-circulation-of-the-omicron-sars-cov-2-variant-from-the-who-technical-
730 advisory-group-on-covid-19-vaccine-composition
731 29 Pfizer plans to manufacture up to 100 million doses of omicron-specific vaccine by
732 spring (*The Washington Post,* 2022);
733 https://www.washingtonpost.com/business/2022/01/11/pfizer-omicron-specific-vaccine/
734 30 Gasteiger, C., Lobo, M., Dalbeth, N. & Petrie, K. J. Patients' beliefs and behaviours are
735 associated with perceptions of safety and concerns in a hypothetical biosimilar switch.
736 *Rheumatology International* **41**, 163-171 (2021).
737 31 Doyle, S. *et al.* What happens to patients who have their asthma device switched without
738 their consent? *Prim Care Respir J* **19**, 131-139 (2010).
739 32 Webster, R. K. & Rubin, G. J. The Effect of Positively Framing Side-Effect Risk in Two
740 Different Formats on Side-Effect Expectations, Informed Consent and Credibility: A
741 Randomised Trial of 16- to 75-Year-Olds in England. *Drug Safety* **43**, 1011-1022 (2020).
742 33 Krishnamurthy, P., Carter, P. & Blair, E. Attribute Framing and Goal Framing Effects in
743 Health Decisions. *Organizational Behavior and Human Decision Processes* **85**, 382-399
744 (2001).
745 34 Levin, I. P., Schnittjer, S. K. & Thee, S. L. Information framing effects in social and
746 personal decisions. *Journal of Experimental Social Psychology* **24**, 520-529 (1988).

747 35 Zimmermann, C., Baldo, C. & Molino, A. Framing of outcome and probability of
748 recurrence: Breast cancer patients' choice of adjuvant chemotherapy (ACT) in
749 hypothetical patient scenarios. *Breast Cancer Research and Treatment* **60**, 9-14 (2000).
750 36 Marteau, T. M. Framing of information: Its influence upon decisions of doctors and
751 patients. *British Journal of Social Psychology* **28**, 89-94 (1989).
752 37 Webster, R. K. & Rubin, G. J. Predicting Expectations of Side-Effects for Those Which
753 Are Warned Versus Not Warned About in Patient Information Leaflets. *Ann Behav Med*
754 **12**, 1253–1261 (2021).
755 38 Herber, O. R., Gies, V., Schwappach, D., Thürmann, P. & Wilm, S. Patient information
756 leaflets: informing or frightening? A focus group study exploring patients' emotional
757 reactions and subsequent behavior towards package leaflets of commonly prescribed
758 medications in family practices. *BMC Family Practice* **15**, 163 (2014).
759 39 Berry, D. C., Raynor, D. K. & Knapp, P. Communicating risk of medication side effects:
760 An empirical evaluation of EU recommended terminology. *Psychology, Health &*
761 *Medicine* **8**, 251-263 (2003).
762 40 *Research and analysis: Coronavirus vaccine - weekly summary of Yellow Card reporting*
763 (gov.uk, 2021); https://www.gov.uk/government/publications/coronavirus-covid-19-
764 vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting
765 41 Myers, J. L. & Well, A. D. *Research design and statistical analysis, 2nd ed*. (Lawrence
766 Erlbaum Associates Publishers, 2003).
767 42 Cardinal, R. N. & Aitken, M. R. F. *ANOVA for the behavioural sciences researcher*.
768 (Lawrence Erlbaum Associates Publishers, 2006).
769 43 Llewellyn-Thomas, H. A., McGreal, M. J. & Thiel, E. C. Cancer Patients' Decision
770 Making and Trial-entry Preferences: The Effects of "Framing" Information about Short-
771 term Toxicity and Long-term Survival. *Medical Decision Making* **15**, 4-12 (1995).
772 44 Ferguson, E. & Gallagher, L. Message framing with respect to decisions about
773 vaccination: The roles of frame valence, frame method and perceived risk. *British*
774 *Journal of Psychology* **98**, 667-680 (2007).
775 45 Jasper, J. D., Goel, R., Einarson, A., Gallo, M. & Koren, G. Effects of framing on
776 teratogenic risk perception in pregnant women. *The Lancet* **358**, 1237-1238 (2001).

46 Webster, R. K., Weinman, J. & Rubin, G. J. Explaining all without causing unnecessary harm: Is there scope for positively framing medical risk information? *Patient Education and Counseling* **102**, 602-603 (2019).

47 Freling, T. H., Vincent, L. H. & Henard, D. H. When not to accentuate the positive: Re-examining valence effects in attribute framing. *Organizational Behavior and Human Decision Processes* **124**, 95-109 (2014).

48 Dan, V. & Dixon, G. N. Fighting the Infodemic on Two Fronts: Reducing False Beliefs Without Increasing Polarization. *Science Communication* **43**, 674-682 (2021).

49 Nyhan, B. & Reifler, J. Does correcting myths about the flu vaccine work? An experimental evaluation of the effects of corrective information. *Vaccine* **33**, 459-464 (2015).

50 Webster, R. K., Weinman, J. & Rubin, G. J. People's Understanding of Verbal Risk Descriptors in Patient Information Leaflets: A Cross-Sectional National Survey of 18- to 65-Year-Olds in England. *Drug Safety* **40**, 743-754 (2017).

51 Berry, D. C., Knapp, P. R. & Raynor, T. Is 15 per cent very common? Informing people about the risks of medication side effects. *International Journal of Pharmacy Practice* **10**, 145-151 (2002).

52 Berry, D. C., Raynor, D. K., Knapp, P. & Bersellini, E. Patients' Understanding of Risk Associated with Medication Use. *Drug Safety* **26**, 1-11 (2003).

53 Knapp, P. *et al.* Communicating the Risk of Side Effects to Patients. *Drug Safety* **32**, 837-849 (2009).

54 Gerend, M. A. & Shepherd, J. E. Predicting Human Papillomavirus Vaccine Uptake in Young Adult Women: Comparing the Health Belief Model and Theory of Planned Behavior. *Annals of Behavioral Medicine* **44**, 171-180 (2012).

55 Lehmann, B. A., Ruiter, R. A. C., Chapman, G. & Kok, G. The intention to get vaccinated against influenza and actual vaccination uptake of Dutch healthcare personnel. *Vaccine* **32**, 6986-6991 (2014).

56 Juraskova, I., Bari, R. A., O'Brien, M. T. & McCaffery, K. J. HPV Vaccine Promotion: Does Referring to Both Cervical Cancer and Genital Warts Affect Intended and Actual Vaccination Behavior? *Women's Health Issues* **21**, 71-79 (2011).

57 Jensen, U., Ayers, S. & Koskan, A. *Video-based messages to reduce COVID-19 vaccine hesitancy and nudge uptake*. Preprint at: https://psyarxiv.com/df9qw/ (2021).

58 Sheeran, P. Intention—Behavior Relations: A Conceptual and Empirical Review. *European Review of Social Psychology* **12**, 1-36 (2002).

59 Kreiner, H. & Gamliel, E. Are highly numerate individuals invulnerable to attribute framing bias? Comparing numerically and graphically represented attribute framing. *European Journal of Social Psychology* **47**, 775-782 (2017).


Pre-Screened Participants
(Total N = 1222)
Previous Vaccine:
AstraZeneca
(AZ = 615)
Previous Vaccine:
Pfizer
(Pf = 607)
PIL: Same as Previous Vaccine
(AZ = 205 / Pf = 205)
PIL: Different / Familiar Vaccine
(AZ = 204 / Pf = 200)
PIL: Different / Unfamiliar Vaccine
(AZ = 206 / Pf = 202)
Positive
(AZ = 103 / Pf = 104)
Negative
(AZ = 102 / Pf = 101)
Positive
(AZ = 101 / Pf = 100)
Negative
(AZ = 103 / Pf = 100)
Positive
(AZ = 103 / Pf = 100)
Negative
(AZ = 103 / Pf = 102)
Baseline Primary Outcome:
Baseline Booster Intention
'If you were offered [framed vaccine type] as a booster vaccine to maintain protection against COVID-19 viruses, how likely would you be to accept?' (100-point VAS)
Baseline Secondary Outcomes:
Baseline Perceived Booster Side effect Severity
'Overall, how severe do you think the [framed vaccine type] side effects are?' (100-point VAS)
Baseline Perceived Booster Risk
'What do you think the risk to your health would be if you received [framed vaccine type] as a booster vaccine, bearing in mind its side effects?' (100-point VAS)
Baseline Booster Acceptance
'Imagine that switching to the [framed vaccine type] vaccine was your only option for a booster. Please rate how satisfied, happy, and anxious, you would be with this outcome' (100-point VAS)
Manipulation: Timed presentation of framed PIL information
Post-Manipulation Primary Outcome:
Booster Intention
Post-Manipulation Secondary Outcomes:
Perceived Booster Side effect Severity
Perceived Booster Risk
Booster Acceptance
Post-Manipulation Judgement of Side Effect Prevalence
Assignment of PIL side effects to verbal risk brackets
Forced choice assignment to very common, common, uncommon, rare and very rare categories
Estimation of prevalence (X in every 100,000 individuals)
Estimation of how many people in every 100,000 affected

Negative Attribute Frame (Standard EU Wording)	Positive Attribute Frame	Positive Attribute Frame (Accompanying Infographic)
Common (may affect up to 1 in 10 people)	**Common** (90 in 100 or more people may ***not be affected***)	 **Common:** 90 in 100 (blue circles) or more **not affected**
Uncommon (may affect up to 1 in 100 people)	**Uncommon** (990 in 1,000 or more people may ***not be affected***)	 **Uncommon:** 990 in 1,000 (blue circles) or more **not affected**

3a. Frequency of Participants by Location



3b. Demographic Information by Condition

Education by Condition



Employment by Condition



Age by Condition



4a. Booster Intention (Framing*Familiarity)



4b. Booster Intention (Framing*Familiarity*Baseline Intention)



4c. AstraZeneca Vaccine Switches



4d. Pfizer Vaccine Switch



4e. Side Effect Familiarity Ratings



Key: Framing Negative Frame Positive Frame

5a. Side Effect Severity (Framing*Baseline Severity)



5b. Perceived Risk (Familiarity*Baseline Risk)



Booster Acceptance

5c. (Framing*Familiarity*Baseline Satisfaction/Happiness)



5d. (Framing*Familiarity*Baseline Anxiety)




6a. Side Effect Category Judgement
Side Effect Category (% Correct)
40
35
30
25
20
15
Unfamiliar
Familiar
Same
Vaccine Familiarity
6b. Side Effect Frequency Judgement
Side Effect Frequency (% Correct)
30
28
26
24
22
20
18
16
Unfamiliar
Familiar
Same
Vaccine Familiarity
Framing
Negative
Positive